Weave Bio

Weave Bio is an AI-native regulatory automation platform built for drug development. Founded in 2023 and headquartered in San Francisco, Weave supports the entire regulatory content lifecycle — from authoring and data extraction to submission publishing and response management. The platform helps pharmaceutical companies, biotech firms, and CROs automate IND filings, HAQ management, and global regulatory submissions. Weave's AI infuses intelligence into every step of the workflow, including data verification, document drafting, and review, enabling regulatory teams to navigate evolving frameworks from agencies such as the FDA faster and with greater confidence. Co-founded by Brandon Rice (CEO) and Ari Caroline (CSO), the company's mission is to equip human regulatory experts with AI tools that reduce time-to-submission without sacrificing quality, ultimately helping life-saving therapies reach patients sooner. Partners include Parexel, and the platform is backed by leading life science investors.